Valsartan/Hydrochlorothiazide ratiopharm 80 mg/12,5 mg Filmdragerad tablett

国家: 瑞典

语言: 瑞典文

来源: Läkemedelsverket (Medical Products Agency)

现在购买

资料单张 资料单张 (PIL)
22-04-2018
产品特点 产品特点 (SPC)
28-04-2018

有效成分:

hydroklortiazid; valsartan

可用日期:

ratiopharm GmbH

ATC代码:

C09DA03

INN(国际名称):

hydrochlorothiazide; valsartan

剂量:

80 mg/12,5 mg

药物剂型:

Filmdragerad tablett

组成:

hydroklortiazid 12,5 mg Aktiv substans; valsartan 80 mg Aktiv substans

类:

Apotek

处方类型:

Receptbelagt

治疗领域:

Valsartan och diuretika

產品總結:

Förpacknings: Blister, 14 tabletter; Burk, 100 tabletter; Blister, 20 tabletter; Blister, 28 tabletter; Blister, 30 tabletter; Blister, 56 tabletter; Blister, 60 tabletter; Blister, 90 tabletter; Blister, 98 tabletter; Blister, 100 tabletter; Blister, 280 tabletter; Burk, 500 tabletter

授权状态:

Godkänd

授权日期:

2010-02-26

资料单张

                                1
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
Valsartan/Hydrochlorothiazide ratiopharm 80 mg/12.5 mg film-coated
tablets
Valsartan/Hydrochlorothiazide ratiopharm 160 mg/12.5 mg film-coated
tablets
Valsartan/Hydrochlorothiazide ratiopharm 160 mg/25 mg film-coated
tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 80 mg valsartan and 12.5 mg
hydrochlorothiazide.
Each film-coated tablet contains 160 mg valsartan and 12.5 mg
hydrochlorothiazide.
Each film-coated tablet contains 160 mg valsartan and 25 mg
hydrochlorothiazide.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet
80 mg/12.5 mg: Light orange, oval shaped film-coated tablet
(dimension: approx. 5.3 x 10.2
mm).
160 mg/12.5 mg: Dark-red, oval shaped film-coated tablets (dimension:
approx. 6.1 x 15.2 mm).
160 mg/25 mg: Brown, oval shaped, film-coated tablet, scored on one
side (dimension: approx.
5.6 x 14.2 mm).
The tablet can be divided into equal doses.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of essential hypertension in adults.
_Valsartan/Hydrochlorothiazide ratiopharm_ is indicated in patients
whose blood pressure is not
adequately controlled on valsartan or hydrochlorothiazide monotherapy.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The recommended dose of _Valsartan/Hydrochlorothiazide ratiopharm _is
one film-coated tablet
once daily. Dose titration with the individual components is
recommended. In each case, up-
titration of individual components to the next dose should be followed
in order to reduce the
risk of hypotension and other adverse events.
When clinically appropriate direct change from monotherapy to the
fixed combination may be
considered in patients whose blood pressure is not adequately
controlled on valsartan or
hydrochlorothiazide monotherapy, provided the recommended dose
titration sequence for the
individual components is followed.
2
The clinical response to _Valsartan/Hydrochlorothiazide ratiopharm
_should be e
                                
                                阅读完整的文件
                                
                            

产品特点

                                MARKNADSFÖRS EJ FÖR NÄRVARANDE.
_Produktinformation_
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 英文 04-05-2022
产品特点 产品特点 英文 04-05-2022
公众评估报告 公众评估报告 英文 21-02-2013